Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 8, 2014, Pages 2104-2115

  Kung, Pei Pei ^a   Martinez, Ricardo ^a,b   Zhu, Zhou ^a   Zager, Michael ^a,e   Blasina, Alessandra ^a   Rymer, Isha ^a   Hallin, Jill ^a   Xu, Meirong ^a   Carroll, Christopher ^a,c   Chionis, John ^a   Wells, Peter ^a   Kozminski, Kirk ^a,f   Fan, Jeffery ^a   Guicherit, Oivin ^a   Huang, Buwen ^a   Cui, Mei ^a   Liu, Chaoting ^a   Huang, Zhongdong ^a,d   Sistla, Anand ^a   Yang, Jennifer ^a,e   Murray, Brion W ^a   more..

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ARENA PHARMACEUTICALS   (United States)

^d Halozyme Therapeutics Inc   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Ferring Pharmaceuticals AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CENTROMERE PROTEIN E; DOCETAXEL; HISTONE H3; KINESIN INHIBITOR; PF 2771; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; GLYCINE; NONHISTONE PROTEIN; PF-2771;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MODEL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASMS, BASAL CELL; SCID MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENE EXPRESSION; GLYCINE; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, SCID; NEOPLASMS, BASAL CELL; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905645099     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0083-T     Document Type: Article

References (45)

1. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227 -41.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
3. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23(Suppl 6): vi7-12.
4. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
6. Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681- 92.
7. Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104-8. (Pubitemid 26156111)
8. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11. (Pubitemid 26156112)
9. Hauf S. The spindle assembly checkpoint: progress and persistent puzzles. Biochem Soc Trans 2013;41:1755- 60.
10. Yen TJ, Compton DA, Wise D, Zinkowski RP, Brinkley BR, Earnshaw WC, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 1991;10:1245-54. (Pubitemid 21905587)
11. Yen TJ, Li G, Schaar BT, Szilak I, Cleveland DW. CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 1992;359:536-9.
12. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
13. Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer 2012;12:527-39.
14. Sawicka A, Seiser C. Histone H3 phosphorylation - a versatile chromatin modification for different occasions. Biochimie 2012;94:2193-201.
15. Wood KW, Chua P, Sutton D, Jackson JR. Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint. Clin Cancer Res 2008;14:7588- 92.
16. Guo Y, Kim C, Ahmad S, Zhang J, Mao Y. CENP-E-dependent BubR1 autophosphorylation enhances chromosome alignment and the mitotic checkpoint. J Cell Biol 2012;198:205-17.
17. Ross JS, Linette GP, Stec J, Ross MS, Anwar S, Boguniewicz A. DNA ploidy and cell cycle analysis in breast cancer. Am J Clin Pathol 2003;120(Suppl):S72- 84.
18. Brown KD, Wood KW, Cleveland DW. The kinesin-like protein CENP-E is kinetochore-associated throughout poleward chromosome segregation during anaphase-A. J Cell Sci 1996;109(Pt 5):961- 9.
19. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975- 88.
20. Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 2010;10:102-15.
21. Yoon DS, Wersto RP, Zhou W, Chrest FJ, Garrett ES, Kwon TK, et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Path 2002;161:391-7. (Pubitemid 36142147)
22. Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012;122:1138-43.
23. Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, et al. Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cell Transl Med 2013;2:233-42.
24. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9:1-17. (Pubitemid 28088174)
25. Guha M. Blockbuster dreams for Pfizer's CDKinhibitor. Nat Biotechnol 2013;31:187.
26. Kim Y, Heuser JE, Waterman CM, Cleveland DW. CENP-E combines a slow, processive motor and a flexible coiled coil to produce an essential motile kinetochore tether. J Cell Biol 2008;181:411-9. (Pubitemid 351645031)
27. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A 2010;107:5839-44.
28. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007;11:25-36. (Pubitemid 46070223)
29. Maiato H, Logarinho E. Motor-dependent and -independent roles of CENP-E at kinetochores: the cautionary tale of UA62784. Chem Biol 2011;18:679-80.
30. Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, et al. UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther 2009;8:36-44.
31. Tcherniuk S, Deshayes S, Sarli V, Divita G, Abrieu A. UA62784 is a cytotoxic inhibitor of microtubules, not CENP-E. Chem Biol 2011;18:631-41.
32. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 2012;69:733-41.
33. Ding X, Yan F, Yao P, Yang Z, Wan W, Wang X, et al. Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin. Cell Res 2010;20:1386-9.
34. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013;73:5315-9.
35. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 2010;4:255-66.
36. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8.
37. Sheltzer JM. A transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosis. Cancer Res 2013;73:6401-12.
38. Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A. Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res 1984;44:394-6. (Pubitemid 14177770)
39. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-8. (Pubitemid 44325930)
40. Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 2010;25:219-28.
41. Silk AD, Zasadil LM, Holland AJ, Vitre B, Cleveland DW, Weaver BA. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proc Natl Acad Sci U S A. 2013;110:E4134-41.
42. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-8. (Pubitemid 27517876)
43. Nijman SM, Friend SH. Cancer. Potential of the synthetic lethality principle. Science 2013;342:809-11.
44. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer J 2004;109:157-62. (Pubitemid 38240914)
45. Pikor L, Thu K, Vucic E, Lam W. The detection and implication of genome instability in cancer. Cancer Metastasis Rev 2013;32:341-52.